1. Acknowledgement to Referees

   Acknowledgement to Referees 02 December 2023 Pages: 1645 - 1647

2. Current and Emerging Treatment Options for Uterine Fibroids

   • Mohamed Ali
   • Michał Ciebiera
   • Ayman Al-Hendy

   Review Article 03 November 2023 Pages: 1649 - 1675

   

3. HIV Pre-Exposure Prophylaxis: New and Upcoming Drugs to Address the HIV Epidemic

   • Christina G. Rivera
   • John D. Zeuli
   • Zelalem Temesgen

   Review Article 11 December 2023 Pages: 1677 - 1698

   

4. Aetiology of Significant Liver Test Abnormalities in a Single-Centre Cohort of People with Cystic Fibrosis Exposed to Elexacaftor/Tezacaftor/Ivacaftor, Utilizing the Updated RUCAM

   • Daniel Tewkesbury
   • Andrew M. Jones
   • Peter J. Barry

   Original Research Article 15 November 2023 Pages: 1699 - 1707

   

5. Momelotinib: First Approval

   • Susan J. Keam

   AdisInsight Report 21 November 2023 Pages: 1709 - 1715

   

6. Iruplinalkib: First Approval

   • Susan J. Keam

   AdisInsight Report 27 November 2023 Pages: 1717 - 1721

   

7. Gepirone Extended-Release: First Approval

   • Susan J. Keam

   AdisInsight Report 11 December 2023 Pages: 1723 - 1728

   

8. Nedosiran: First Approval

   • Yahiya Y. Syed

   AdisInsight Report Open access 07 December 2023 Pages: 1729 - 1733

   

9. Correction: Elacestrant: First Approval

   • Sheridan M. Hoy

   Correction Open access 25 November 2023 Pages: 1735 - 1735

10. Correction to: Motixafortide: First Approval

    • Sheridan M. Hoy

    Correction 07 December 2023 Pages: 1737 - 1737